Scleroderma renal crisisMANAGEMENT

MUSCULOSKELETAL AND RHEUMATOLOGIC PRESENTATIONS · 12 SECTIONS

⚲

463 items

☷ Legend

01Approach to the Critical Patient/attcp35

Immediate priorities

›Scleroderma renal crisis is new severe hypertension plus rapidly rising creatinine in a patient with systemic sclerosis

›Suspect it with any acute creatinine rise in known or suspected systemic sclerosis, especially diffuse cutaneous disease within 4 years of onset

›Blood pressure above 150/85 mmHg that is new or a rise of more than 20 mmHg systolic over the patient's baseline is the classic trigger

›Compare against the patient's own usual readings, which in systemic sclerosis often run low

›Roughly 10 percent of cases are normotensive at presentation and carry a worse prognosis

›Thrombotic microangiopathy features frequently accompany it: new anemia, thrombocytopenia below 150 x10^9/l, schistocytes, low haptoglobin, high lactate dehydrogenase

›Start a short-acting ACE inhibitor as soon as the diagnosis is suspected

›Captopril 6.25 to 12.5 mg orally is the first dose; do not wait for confirmatory serology, renin, or biopsy

›A rising creatinine after starting the ACE inhibitor is expected and is not a reason to stop

›The goal is controlled, gradual blood pressure reduction, not rapid normalization

›Identify and remove precipitants immediately

›Corticosteroids at 15 mg prednisone equivalent per day or higher are the leading iatrogenic precipitant

›Stop nephrotoxins: NSAIDs, iodinated contrast, calcineurin inhibitors where feasible

›Do not volume-load; these patients are renin-driven and vasoconstricted, not hypovolemic

›Escalate care early

›ICU-level monitoring for hourly blood pressure and neurologic checks and for hyperkalemia risk

›Emergent nephrology and rheumatology involvement, with early dialysis planning

›Transfer to a center with scleroderma and renal replacement expertise if these are unavailable

Resuscitation cautions and mimics

›The specific way routine care harms this patient

›Aggressive blood pressure lowering drives renal and cerebral hypoperfusion because autoregulation is shifted and the kidney is already ischemic

›Lower systolic pressure by no more than 20 mmHg in the first 24 hours toward the patient's baseline

›Precipitous drops can convert recoverable injury into dialysis dependence or watershed infarction

›Crystalloid loading precipitates pulmonary edema in a hypertensive patient who may also have scleroderma myocardial disease or a pericardial effusion

›Beta blockers worsen renal and digital vasospasm and do not address the renin-angiotensin drive

›High-dose corticosteroids given reflexively for a presumed flare can precipitate or worsen the crisis

›Do not anchor on scleroderma renal crisis without excluding look-alikes

02History/hx38

Systemic sclerosis background

›Established or suspected systemic sclerosis, and the cutaneous subtype

›Diffuse cutaneous disease carries the great majority of renal crisis risk

›Limited cutaneous disease and scleroderma renal crisis together are uncommon and should prompt a search for an alternative diagnosis

›Disease duration from the first non-Raynaud manifestation

›About three quarters of cases occur within 4 years of onset

›Peak risk is in the first 1 to 3 years of rapidly progressive disease

›Rapidly progressive skin thickening over the preceding 3 to 6 months

›New tendon friction rubs, which are a recognized marker of renal crisis risk

›Known autoantibody profile

›Anti-RNA polymerase III is strongly associated and present in roughly half to two thirds of renal crisis patients

›Anti-centromere positivity makes the diagnosis much less likely and should trigger reconsideration

›Anti-topoisomerase I (anti-Scl-70) is more associated with an overlap vasculitis picture

›Prior episode of scleroderma renal crisis

›Recent unexplained heart failure or a new pericardial effusion, which can precede the crisis

Precipitants and exposures

›Corticosteroid exposure: agent, dose, and duration

›Prednisone at 15 mg per day equivalent or higher within the preceding weeks is the highest-yield precipitant to identify

›Any recent pulse methylprednisolone

›Nephrotoxin exposure

›NSAIDs including over-the-counter ibuprofen and naproxen

›Iodinated contrast within the preceding days

›Ciclosporin or tacrolimus

›Cocaine or sympathomimetic use

›Missed or reduced antihypertensive doses, and any recent medication changes

›Volume depletion from diuretics, vomiting, or diarrhea, which can unmask or worsen the crisis

›Pregnancy or delivery within the preceding weeks

›Recent home blood pressure readings and the patient's documented baseline

03Physical Exam/exam22

Vital signs, retina, and hemodynamics

›Blood pressure measured in both arms, and compared with the patient's baseline

›Commonly above 150/90 mmHg and often above 200/120 mmHg

›A reading within the population-normal range can still represent crisis-level hypertension for a patient whose baseline systolic is 95 to 105 mmHg

›Orthostatic vitals to detect superimposed volume depletion before starting the ACE inhibitor

›Heart rate and rhythm; irregularity may reflect scleroderma conduction disease

›Oxygen saturation and respiratory rate; target saturation is 94 to 98 percent, or 88 to 92 percent if there is coexisting chronic hypoxemic lung disease or pulmonary hypertension

›Urine output measured hourly once a catheter is placed; oliguria is below 0.5 ml/kg/hour

›Fundoscopy for grade III to IV hypertensive retinopathy: flame hemorrhages, cotton-wool spots, papilledema

›Volume assessment: jugular venous pressure, an S3 gallop, bibasilar crackles, and peripheral edema pointing to pulmonary edema rather than hypovolemia

Skin, cardiopulmonary, and neurologic findings

›Cutaneous and musculoskeletal signs of diffuse systemic sclerosis

›Diffuse skin thickening proximal to the elbows and knees and over the trunk

›Puffy edematous hands and rapidly worsening sclerodactyly

›Tendon friction rubs palpable over wrists, ankles, or knees

›Digital pitting scars, active digital ulcers, and calcinosis

›Microstomia, perioral furrowing, and mucocutaneous telangiectasia

›Nailfold capillary dropout on bedside capillaroscopy or ophthalmoscope inspection

›Cardiopulmonary findings

›Pericardial friction rub or signs of tamponade: pulsus paradoxus, muffled heart sounds, elevated jugular venous pressure

›Pulmonary crackles and hypoxemia from acute pulmonary edema

›Neurologic and hematologic findings

›Encephalopathy signs: altered mentation, hyperreflexia, focal deficit, or seizure activity

›Pallor of conjunctivae and palmar creases reflecting new anemia

04Differential Diagnosis/ddx26

Hypertensive and renin-driven mimics

›Conditions producing severe hypertension that mimic renal crisis

›Hypertensive emergency from essential hypertension or antihypertensive non-adherence, which is more common than renal crisis and is rapidly treatable

›Scleroderma renal crisis, the diagnosis in question, favored by diffuse early disease, anti-RNA polymerase III, and a bland or mildly abnormal urinary sediment

›Pheochromocytoma or hyperadrenergic crisis: paroxysmal hypertension, sweating, headache, palpitations; send plasma free metanephrines

›Renovascular hypertension or acute renal artery occlusion

›Cocaine or sympathomimetic toxicity

›Posterior reversible encephalopathy syndrome as a consequence rather than a separate cause

Thrombotic microangiopathy differential

›Other causes of microangiopathic hemolytic anemia with organ injury

›Thrombotic thrombocytopenic purpura: ADAMTS13 activity below 10 percent, more neurologic involvement, less prominent hypertension; the highest-stakes miss

›Complement-mediated (atypical) hemolytic uremic syndrome

›Shiga toxin-associated hemolytic uremic syndrome with a diarrheal prodrome

›Catastrophic antiphospholipid syndrome: multi-organ thrombosis, positive antiphospholipid antibodies

›Drug-induced thrombotic microangiopathy: calcineurin inhibitors, gemcitabine, bevacizumab, quinine

›Malignant hypertension of any cause producing secondary microangiopathic hemolysis

›Preeclampsia, HELLP syndrome, or pregnancy-associated thrombotic microangiopathy in the peripartum period

›Disseminated intravascular coagulation, distinguished by a prolonged prothrombin time and low fibrinogen

Other renal and systemic causes

›Alternative renal and systemic diagnoses to exclude

›ANCA-associated vasculitis or a scleroderma-vasculitis overlap: hematuria, red-cell casts, often normotensive, ANCA positive

›Other rapidly progressive glomerulonephritis, including anti-GBM disease

›Acute tubular necrosis from hypoperfusion, sepsis, or nephrotoxins

›Acute interstitial nephritis, often drug-induced

›Prerenal azotemia from diuretics or gastrointestinal losses

›Cardiorenal syndrome from primary scleroderma myocardial disease or pericardial tamponade

›Obstructive uropathy, excluded on ultrasound

›Cholesterol embolization after recent arterial catheterization

05Laboratory Tests/lt44

Renal function and electrolytes

›Serum creatinine now and repeated every 8 to 12 hours to quantify the rate of rise

›A doubling from baseline over days, or an absolute value above 265 micromol/l at presentation, marks severe disease and worse prognosis

›Establish the pre-crisis baseline from prior records wherever possible

›Serum urea for the degree of uremia and dialysis planning

›Potassium every 8 to 12 hours, and more often once above 5.5 mmol/l, because acute kidney injury plus an ACE inhibitor compounds hyperkalemia risk

›Sodium, bicarbonate, chloride, and calculated anion gap for metabolic acidosis

›Magnesium and phosphate, which rise with worsening clearance

›Venous blood gas for pH and bicarbonate when acidosis is suspected

›Urinalysis with microscopy: mild proteinuria and a bland or minimally active sediment are typical

›Urine protein-to-creatinine ratio; nephrotic-range proteinuria points away from renal crisis

›Point-of-care glucose, since encephalopathic or vomiting patients can be hypoglycemic and the picture overlaps

Microangiopathic hemolysis panel

›Tests that establish a thrombotic microangiopathy

›Complete blood count with platelet count; a falling platelet count below 150 x10^9/l supports thrombotic microangiopathy

›Hemoglobin, with attention to a new or accelerating drop

›Peripheral blood smear for schistocytes

›Lactate dehydrogenase, elevated from both hemolysis and renal tissue injury

›Haptoglobin, low in intravascular hemolysis

›Reticulocyte count, elevated in a compensatory response

›Direct antiglobulin (Coombs) test, expected negative in a mechanical hemolysis

›Unconjugated bilirubin

›Tests that separate microangiopathy from consumptive coagulopathy and track its course

›Prothrombin time, activated partial thromboplastin time, and fibrinogen to separate thrombotic microangiopathy from disseminated intravascular coagulation

›Daily repeat of platelets, lactate dehydrogenase, and haptoglobin to track the microangiopathic course and response

Serologic and autoantibody testing

›Autoantibodies that frame the systemic sclerosis context

›Antinuclear antibody with pattern

06Diagnostic Tests/dt44

Scoring Systems

›No validated diagnostic or prognostic score exists for scleroderma renal crisis

›Diagnosis is clinical: new severe hypertension plus acute kidney injury in systemic sclerosis, with supportive thrombotic microangiopathy and, when obtained, characteristic biopsy findings

›Do not apply a fabricated tier or cutoff to stage severity

›Risk stratification instead relies on recognized markers, not a composite score

›Diffuse cutaneous subtype, disease duration under 4 years, rapidly progressive modified Rodnan skin score, new tendon friction rubs

›Anti-RNA polymerase III positivity, new anemia, and a recent pericardial effusion or heart failure

›Corticosteroid exposure at 15 mg prednisone equivalent per day or more

›Prognostic features once the crisis is established

›Male sex, older age, creatinine above 265 micromol/l at presentation, congestive heart failure, and normotensive presentation predict worse renal and survival outcomes

›Failure to control blood pressure within 3 days predicts dialysis dependence

MRI

›MRI is not part of the routine renal crisis workup

›Brain MRI is indicated when encephalopathy, seizure, or focal deficit raises posterior reversible encephalopathy syndrome

›Typical finding is vasogenic edema in the parieto-occipital white matter, usually reversible with blood pressure control

›Gadolinium is contraindicated in severe acute kidney injury because of nephrogenic systemic fibrosis risk; obtain non-contrast sequences

›Cardiac MRI is reserved for later characterization of scleroderma myocardial fibrosis and is not an emergency test

›Non-contrast CT head for acute neurologic change, seizure, or suspected intracranial hemorrhage from severe hypertension

›CT chest without contrast if pulmonary edema is difficult to distinguish from infection or fibrosis on plain film

›Avoid iodinated contrast while creatinine is rising

›If contrast is unavoidable, use the minimum volume, maintain the ACE inhibitor and euvolemia, and never delay blood pressure control for a scan

›CT abdomen is not required for diagnosis and adds contrast and radiation without changing management

Ultrasound

›Renal ultrasound with Doppler

›Kidneys are typically normal-sized or slightly enlarged with increased cortical echogenicity in acute renal crisis

›Small echogenic kidneys with cortical thinning indicate chronic disease and a lower chance of recovery

›Excludes hydronephrosis and obstruction

›Elevated resistive indices are nonspecific but consistent with the vascular injury

›Bedside lung ultrasound for B-lines to confirm pulmonary edema and guide against fluid loading

›Focused echocardiography at the bedside and formal transthoracic echocardiography

›Pericardial effusion and tamponade physiology

›Left ventricular systolic function and regional wall motion for scleroderma myocardial involvement

›Estimated pulmonary artery systolic pressure for coexisting pulmonary hypertension, which changes oxygenation targets

›Inferior vena cava assessment to corroborate that the patient is not volume-depleted before ACE inhibitor initiation

Renal biopsy

›Percutaneous renal biopsy confirms the diagnosis and distinguishes renal crisis from vasculitis and other glomerulonephritis

›Characteristic findings: myxoid intimal expansion, onion-skin concentric proliferation of interlobular arteries, fibrinoid necrosis, glomerular ischemic collapse, and thrombotic microangiopathy

›Immunosuppression-responsive alternatives such as pauci-immune crescentic glomerulonephritis look different and mandate a different therapy

›Timing and safety

›Defer while blood pressure is uncontrolled or the platelet count is below 50 to 100 x10^9/l because of bleeding risk

›Do not delay ACE inhibitor therapy to obtain a biopsy

›Biopsy is most useful when the presentation is atypical: normotensive, anti-centromere positive, active urinary sediment, or ANCA positive

ECG

›Twelve-lead ECG at presentation and repeated with any potassium change

›Hyperkalemia from acute kidney injury plus the ACE inhibitor: peaked T waves, PR prolongation, P-wave flattening, then QRS widening toward a sine wave

›Left ventricular hypertrophy and strain from chronic and acute hypertension

›Conduction delay, AV block, or atrial and ventricular ectopy from scleroderma myocardial fibrosis

›Low voltage or electrical alternans with a large pericardial effusion

›Continuous cardiac monitoring during active antihypertensive titration and while potassium is above 5.5 mmol/l

07Disposition/dispo27

Level of care

›ICU or high-dependency admission for any patient with active renal crisis

›Hourly blood pressure and neurologic checks during titration

›Arterial line when intravenous antihypertensives are used

›Continuous ECG monitoring for hyperkalemia and arrhythmia

›Admit even when blood pressure responds quickly in the emergency department

›Serial creatinine, potassium, and the microangiopathy panel still need 48 to 72 hours of observation

›Normotensive renal crisis requires admission because its prognosis is worse and the diagnosis is often delayed

›Place a urinary catheter for strict hourly output and daily weights

Consultations

›Specialists to involve on the day of presentation

›Nephrology emergently for titration guidance, biopsy decision, and dialysis planning and access

›Rheumatology emergently to confirm the systemic sclerosis context, review immunosuppression, and coordinate longitudinal care

›Critical care for hemodynamic monitoring and renal replacement therapy

›Maternal-fetal medicine immediately if the patient is pregnant

›Consultations driven by specific findings

›Ophthalmology for documentation of hypertensive retinopathy when the diagnosis is uncertain

›Vascular access or interventional radiology for a dialysis catheter when renal replacement is anticipated

›Hematology when ADAMTS13 is pending and thrombotic thrombocytopenic purpura cannot be excluded

Transfer criteria

›Transfer to a tertiary center with systemic sclerosis expertise when the presenting hospital lacks any of the following

›ICU capacity for invasive blood pressure monitoring

›Nephrology and inpatient renal replacement therapy

›Renal biopsy capability

›Apheresis, if thrombotic thrombocytopenic purpura cannot be excluded

›Stabilize before and during transfer

›Start oral captopril before departure and continue it en route

›Have a short-acting intravenous agent such as nicardipine available for breakthrough hypertension in transit

08Treatment/t108

Blood pressure targets and pace

›The target is a gradual, controlled return toward the patient's own baseline, not rapid normalization

›Lower systolic pressure by no more than 20 mmHg, or mean arterial pressure by no more than 25 percent, in the first 24 hours

›Aim to reach the patient's pre-crisis baseline over 48 to 72 hours

›A daily fall of 10 to 20 mmHg systolic is a reasonable trajectory once the initial reduction is achieved

›Thresholds carry population-specific exceptions

›In normotensive renal crisis the goal is the patient's true baseline, which may be a systolic of 95 to 110 mmHg; a population-normal reading can still be too high

›Long-standing chronic hypertension, older age, or cerebrovascular disease: reduce more slowly to protect a rightward-shifted autoregulation curve

›Pregnancy: coordinate targets with maternal-fetal medicine, generally systolic 110 to 140 mmHg and diastolic 85 to 105 mmHg

›Established dialysis dependence: control interdialytic pressure and volume rather than chase an absolute number

›Overshoot is dangerous

›A precipitous drop worsens renal ischemia, can precipitate dialysis dependence, and risks watershed cerebral and retinal infarction

›If the pressure falls too fast, reduce or hold the last dose increment rather than giving fluid boluses or vasopressors

ACE inhibitor therapy

›Captopril is the first-line agent and the cornerstone of treatment

›Captopril 6.25 to 12.5 mg orally as the first dose

›Increase by 12.5 to 25 mg per dose every 4 to 8 hours as blood pressure and the trajectory allow

›Slow to smaller 6.25 to 12.5 mg increments once systolic pressure approaches within 20 mmHg of the baseline target to avoid overshoot

›Usual effective range is 75 to 150 mg per day divided every 6 to 8 hours

›Maximum approximately 300 to 450 mg per day divided every 6 to 8 hours

›If the patient is volume-depleted or borderline hypotensive, correct volume first with a modest isotonic bolus and start at the 6.25 mg dose

›The short half-life is deliberate: it allows rapid up-titration and quick reversal if pressure drops too far

›Continue the ACE inhibitor through a rising creatinine

›A rise of up to 30 percent over baseline is hemodynamically expected and acceptable

›Continue even beyond that threshold if blood pressure is being brought to target and potassium is manageable, because ACE inhibition is what preserves the chance of renal recovery

›Continue the ACE inhibitor even after dialysis is started; up to half of dialysis-dependent patients recover enough renal function to stop dialysis, sometimes only after 6 to 24 months

›Monitor potassium every 8 to 12 hours; treat hyperkalemia medically and with dialysis rather than by stopping the ACE inhibitor

›Transition planning

›Once blood pressure is stable at target for 24 to 48 hours, convert to a once- or twice-daily long-acting ACE inhibitor such as lisinopril 10 to 40 mg daily, enalapril 10 to 20 mg twice daily, or ramipril 5 to 10 mg daily, matching the total captopril effect

›The ACE inhibitor is continued indefinitely after discharge

›If oral intake is impossible, enalaprilat 0.625 to 1.25 mg intravenously every 6 hours is an option, but oral captopril is preferred for its finer titratability; resume oral dosing as soon as feasible

Add-on antihypertensives for refractory crisis

›Add a second agent, do not substitute, when maximal captopril has not reached target within 24 hours

›Dihydropyridine calcium channel blocker as the preferred second agent

›This class is an arterial vasodilator and is additive to renin-angiotensin blockade; it does not replace it

›Amlodipine 5 mg orally daily, increased to 10 mg daily after 24 to 48 hours as needed

›Nifedipine extended-release 30 to 60 mg orally daily where amlodipine is unavailable

›Nicardipine intravenous infusion when oral therapy is not tolerated or control is urgent

›Start 5 mg per hour

›Titrate by 2.5 mg per hour every 5 to 15 minutes to effect

›Reduce and widen the titration interval as pressure approaches target to prevent overshoot

›Maximum 15 mg per hour

›Transition to oral amlodipine and captopril once stable and taking oral medication

›Clevidipine 1 to 2 mg per hour intravenously, doubled no more often than every 90 seconds initially then every 5 to 10 minutes, usual range 4 to 6 mg per hour, maximum 32 mg per hour and no more than 1000 ml (21 mg per hour averaged) of the lipid emulsion per 24 hours, is an alternative where available

›Angiotensin receptor blocker as a third agent

›Add losartan 25 to 50 mg orally daily (maximum 100 mg per day) or valsartan 80 to 160 mg orally daily only as an adjunct when blood pressure remains above target on maximal ACE inhibitor plus a calcium channel blocker

›Do not use an angiotensin receptor blocker in place of the ACE inhibitor: the survival benefit is established only for ACE inhibitors, and substitution has been associated with worse outcomes

›Combined ACE inhibitor and angiotensin receptor blocker increases hyperkalemia and acute kidney injury risk; monitor potassium and creatinine every 8 to 12 hours

›Additional agents for truly refractory hypertension, added stepwise with specialist input

›Hydralazine 10 mg intravenously every 4 to 6 hours, titrated to 20 mg, as a direct arteriolar vasodilator bridge

›Minoxidil 2.5 to 5 mg orally twice daily, increased to a maximum of 40 mg per day, for resistant cases, accepting reflex tachycardia and fluid retention

›Intravenous labetalol and other beta blockers are generally avoided because beta blockade aggravates renal and digital vasospasm; reserve only for a specific coexisting indication such as aortic pathology

›Sodium nitroprusside is discouraged because cyanide and thiocyanate accumulate in renal failure; if used, limit to under 2 micrograms per kg per minute for under 24 hours with thiocyanate monitoring

Renal replacement therapy

›Indications are the standard ones: refractory hyperkalemia, refractory volume overload with pulmonary edema, severe metabolic acidosis, and uremic complications

›Roughly half of patients need dialysis during the acute crisis

›Modality

›Intermittent hemodialysis when hemodynamically tolerated

›Continuous renal replacement therapy if hemodynamically unstable or with cerebral edema

›Peritoneal dialysis is a reasonable longer-term option and may aid ultrafiltration without vascular access

›Continue the ACE inhibitor throughout dialysis

›Renal recovery allowing dialysis discontinuation occurs in a substantial minority, often not until 6 to 24 months

›Because of this recovery potential, defer decisions about a permanent access strategy and transplant listing, typically for at least 18 to 24 months

›Anticoagulation for the dialysis circuit: use regional citrate or a reduced-dose heparin protocol, weighed against bleeding risk from severe hypertension and any recent biopsy

Adjuncts, thrombotic microangiopathy, and therapies to avoid

›Thrombotic microangiopathy in renal crisis is driven by the vascular injury and usually resolves as blood pressure is controlled

›Plasma exchange is not routinely beneficial and does not replace ACE inhibition

›Reserve plasma exchange for when thrombotic thrombocytopenic purpura cannot be excluded and ADAMTS13 is pending with high suspicion; start it without delaying the ACE inhibitor, and stop it once ADAMTS13 returns above 10 percent

›Eculizumab has only anecdotal support in refractory, biopsy-proven, complement-mediated microangiopathy; it requires meningococcal vaccination and antibiotic prophylaxis and should not divert from blood pressure control

›Corticosteroids

›Avoid entirely for the renal crisis itself; taper any existing steroid to below 15 mg prednisone equivalent per day, or to the lowest tolerable dose, as fast as the primary indication allows

›If steroids are unavoidable for a separate life-threatening scleroderma manifestation, treat blood pressure and renal function as high-alert and monitor daily

›Disease-directed immunosuppression is not indicated for uncomplicated renal crisis

›It is considered only when biopsy or serology shows a concurrent vasculitis or crescentic glomerulonephritis

›Iatrogenic-harms walk-through for routine emergency interventions

›Intubation and sedation: anticipate a difficult airway from microstomia and neck tightening; expect abrupt hypotension after induction in a renin-dependent state; use etomidate 0.3 mg per kg or reduced-dose propofol, avoid a ketamine-driven pressure surge during a hypertensive emergency, and have a push-dose vasoconstrictor ready for transient post-induction hypotension only

›Fluid loading: withhold empiric boluses; give a 250 to 500 ml isotonic aliquot only for demonstrated hypovolemia, then reassess with lung ultrasound

›Oxygen: titrate to 94 to 98 percent, or 88 to 92 percent with chronic hypoxemic lung disease or pulmonary hypertension; hyperoxia offers no benefit

›Vasopressors: avoid; they intensify the renal vasoconstriction that defines the disease. If iatrogenic hypotension occurs, hold antihypertensives and reduce ultrafiltration rather than starting a pressor

›Mechanical circulatory support including the intra-aortic balloon pump: not indicated; there is no cardiogenic shock target and femoral vascular disease is common

›Anticoagulation: no role for the microangiopathy; use only for a separate indication and dose-adjust for renal function

›Fibrinolysis: contraindicated; there is no large-vessel thrombotic target and severe hypertension makes intracranial hemorrhage risk unacceptable

›Analgesia and antipyresis: avoid all NSAIDs, which cut renal perfusion, blunt the compensatory prostaglandin vasodilation, and raise blood pressure. Use paracetamol (acetaminophen) 1 g orally or intravenously every 6 hours, maximum 3 g per day in older, low-weight, or hepatically impaired patients and 4 g per day otherwise. For opioids, use fentanyl or hydromorphone at reduced dose and avoid morphine because its active metabolite accumulates in renal failure

›Contrast imaging: defer iodinated and gadolinium contrast while creatinine is rising; use non-contrast studies

Monitoring cadence

›Blood pressure every 15 to 30 minutes during active titration, hourly once within 20 mmHg of target, then every 2 to 4 hours when stable

›Continuous arterial line whenever an intravenous antihypertensive infusion is running

›Creatinine, urea, and potassium every 8 to 12 hours, and every 4 to 6 hours once potassium exceeds 5.5 mmol/l or is being actively treated

›Complete blood count, lactate dehydrogenase, and haptoglobin daily to follow the microangiopathic course

›Hourly urine output and twice-daily fluid balance, with daily weights

›Neurologic checks every 1 to 2 hours during titration to catch both hypertensive encephalopathy and over-rapid correction

›Twelve-lead ECG with each significant potassium change; continuous telemetry until potassium is stable below 5.5 mmol/l and blood pressure is controlled

›Daily fundoscopy or symptom review while retinopathy is present

›Reassess volume status with lung and inferior vena cava ultrasound before and after any fluid or diuretic decision

When therapy is not working

›Define failure as blood pressure not at target within 24 to 72 hours on maximal captopril, or a creatinine that continues to climb steeply after 72 hours of controlled pressure

›Escalate antihypertensives

›Add a dihydropyridine calcium channel blocker, then an angiotensin receptor blocker, then hydralazine or minoxidil, as above, each as an addition

›Switch to an intravenous nicardipine or clevidipine infusion with arterial line monitoring if oral absorption is in doubt

›Confirm the fundamentals

›Verify true adherence and actual doses given; look for held doses and absorption failure from scleroderma bowel disease

›Reassess volume status; both occult overload and over-diuresis stall blood pressure control

›Exclude a pericardial effusion with tamponade or a scleroderma myocardial crisis contributing to the hemodynamics

›Reconsider the diagnosis

›Send or review ADAMTS13; if below 10 percent, treat as thrombotic thrombocytopenic purpura with plasma exchange

›Send or review ANCA and antiphospholipid antibodies; proceed to renal biopsy for a vasculitis or crescentic glomerulonephritis that needs immunosuppression

›Reconsider pheochromocytoma, cocaine, and renovascular disease

›In biopsy-proven refractory complement-mediated microangiopathy, discuss eculizumab with nephrology

›Lab-interpretation traps that redirect management

›A creatinine rise up to 30 percent after starting the ACE inhibitor is expected and is not treatment failure; do not stop the drug

›Schistocytes and thrombocytopenia are not sufficient to diagnose thrombotic thrombocytopenic purpura here; anchor on ADAMTS13

›A bland sediment with mild proteinuria is typical; red-cell casts or nephrotic-range proteinuria point away from renal crisis

›A normal blood pressure does not exclude the crisis; compare with the patient's low baseline

›Elevated lactate dehydrogenase reflects both hemolysis and renal injury; interpret with haptoglobin and the smear

›Anti-centromere positivity should lower the pretest probability and prompt biopsy

09Special Populations/sp43

Pregnancy

›Scleroderma renal crisis in pregnancy overlaps closely with preeclampsia and HELLP syndrome

›Shared features: hypertension, acute kidney injury, microangiopathic hemolysis, thrombocytopenia

›Points toward renal crisis: very high renin, a steep isolated creatinine rise, disproportionately severe hypertension, diffuse cutaneous scleroderma of recent onset, and onset that is not confined to after 20 weeks

›Points toward preeclampsia: gestational age over 20 weeks, marked proteinuria with a rising uric acid, an abnormal soluble fms-like tyrosine kinase 1 to placental growth factor ratio, and resolution after delivery

›ACE inhibitors are ordinarily contraindicated in pregnancy

›Fetal risks are oligohydramnios, fetal renal tubular dysgenesis and anuria, calvarial hypoplasia, and growth restriction, mainly with second- and third-trimester exposure

›However, untreated scleroderma renal crisis is frequently fatal for the mother, and in confirmed renal crisis the maternal indication is life-threatening

›The accepted approach is to use an ACE inhibitor, usually captopril or enalapril, when renal crisis is diagnosed in pregnancy, with fully informed consent and close fetal surveillance, because the alternative is maternal death

›Manage jointly with maternal-fetal medicine, nephrology, and rheumatology, monitor amniotic fluid volume serially, and plan delivery when the fetus is viable and maternal disease allows

›Bridging and alternative agents before an ACE inhibitor decision, or when pregnancy is very early

›Labetalol and pure beta blockade are relatively avoided in scleroderma because of vasospasm, but a dihydropyridine is pregnancy-compatible: nifedipine extended-release 30 to 60 mg orally daily, or intravenous nicardipine 5 mg per hour titrated by 2.5 mg per hour every 5 to 15 minutes to a maximum of 15 mg per hour

›Intravenous hydralazine 5 to 10 mg every 20 to 30 minutes for acute severe hypertension

›Magnesium sulfate 4 to 6 g intravenously over 20 minutes then 1 to 2 g per hour if eclampsia cannot be excluded

›Verify against current obstetric guideline before use

›Reduce the infusion and monitor levels closely in renal impairment because magnesium is renally cleared

›Delivery is often required for maternal stabilization; corticosteroids for fetal lung maturity must be weighed against their role in precipitating renal crisis and given only with heightened blood pressure and renal monitoring

Geriatric

›Prognosis and blood pressure targets in older patients

›Older age independently predicts worse renal and survival outcomes in renal crisis

›Baseline chronic hypertension shifts the autoregulatory range; reduce blood pressure more slowly and target the documented pre-crisis baseline rather than a population-normal number

›Higher risk of over-reduction causing cerebral, cardiac, and renal hypoperfusion; start captopril at 6.25 mg and titrate in smaller increments

›Renal, electrolyte, and medication considerations

›Acute kidney injury superimposed on chronic kidney disease is common; hyperkalemia develops faster on an ACE inhibitor, so check potassium every 8 hours

›Review the full medication list for NSAIDs, potassium supplements, potassium-sparing diuretics, and salt substitutes, and stop them

›Polypharmacy raises the chance that a recently added corticosteroid or nephrotoxin precipitated the crisis

›Use paracetamol at a maximum of 3 g per day and reduce opioid doses for age-related renal decline

10Background/b30

Epidemiology

›Frequency and risk associations

›Scleroderma renal crisis affects roughly 5 percent of all patients with systemic sclerosis

›It occurs in about 10 to 15 percent of diffuse cutaneous systemic sclerosis and in only about 1 to 2 percent of limited cutaneous disease

›Around three quarters of episodes occur within 4 years of the first non-Raynaud symptom, with peak incidence in the first 1 to 3 years

›Anti-RNA polymerase III antibodies are present in roughly 60 percent of renal crisis patients and confer an approximately 3- to 4-fold increased risk

›Corticosteroid exposure at 15 mg prednisone equivalent per day or higher is associated with an odds ratio of about 4 to 5 for developing renal crisis

›Approximately 10 percent of cases are normotensive at presentation; these are more often associated with prior corticosteroids, more severe microangiopathy, and a worse prognosis

›Outcomes and trends

›Renal replacement therapy is required in about 40 to 50 percent of cases acutely; of those, roughly a third to a half regain enough function to stop dialysis, often between 6 and 24 months

›Before ACE inhibitors, 1-year mortality exceeded 75 percent with a median survival near 1 month; with modern therapy 1-year survival is about 70 to 85 percent and 5-year survival roughly 55 to 65 percent

›Incidence has declined over recent decades, attributed partly to more cautious corticosteroid use

Pathophysiology

›The primary lesion is injury to the renal interlobular and arcuate arteries

›Endothelial injury leads to myxoid intimal expansion, concentric onion-skin proliferation of smooth muscle, and fibrinoid necrosis

›Luminal narrowing produces cortical ischemia and glomerular collapse

›Ischemia of the juxtaglomerular apparatus triggers massive renin release

›Renin drives angiotensin II generation, causing intense vasoconstriction and a further rise in blood pressure

›The hypertension itself worsens the vascular injury, creating a self-amplifying loop that an ACE inhibitor interrupts at the angiotensin-converting step

›Endothelial damage exposes subendothelial matrix and activates platelets, producing a thrombotic microangiopathy with mechanical hemolysis and consumptive thrombocytopenia

›Triggers that tip a susceptible vasculature into crisis include high-dose corticosteroids, which may act via effects on vascular tone and endothelin, calcineurin inhibitors, cocaine, volume depletion, and possibly cold exposure

›ADAMTS13 activity is normal or only mildly reduced, which distinguishes the microangiopathy from thrombotic thrombocytopenic purpura

›Persistently elevated endothelin-1 contributes to the vasoconstriction and is the rationale behind investigational endothelin receptor antagonism

Therapeutic Considerations

›ACE inhibitors are the only therapy with a demonstrated survival and renal-recovery benefit and must be started early and continued indefinitely, including on dialysis

›Prophylactic ACE inhibitor use to prevent renal crisis in high-risk patients is not recommended and may be harmful

›Observational data associate background ACE inhibitor use at the time of crisis onset with worse outcomes, possibly by blunting the hypertensive warning sign and delaying diagnosis

›High-risk patients should instead do home blood pressure monitoring and present early for a systolic rise of more than 20 mmHg or a reading above 140/90 mmHg

11Patient Discharge Instructions/pdi24

Warning signs reviewed before discharge

›Checks to complete before the patient leaves

›Confirm the patient can state the blood pressure number that should prompt a call and can demonstrate the home monitor

›Confirm the patient understands the ACE inhibitor is not to be stopped for any reason without the kidney specialist

›Confirm follow-up blood tests and appointments are booked before the patient leaves

›Confirm the patient has a written list of medicines to avoid, including all anti-inflammatory painkillers and potassium-containing salt substitutes

›Confirm a dialysis schedule and transport plan are in place if renal replacement was started

copy discharge instructions

›You were treated for scleroderma renal crisis, a sudden problem with blood pressure and kidney function caused by your scleroderma

›Take your blood pressure medicine (for example captopril or lisinopril) every single day, exactly as prescribed

›Do not stop it even if you feel well, and even if you are told your kidney blood test went up; this medicine is what protects your kidneys

›Only your kidney or rheumatology specialist should change the dose

›Check your blood pressure at home twice a day, morning and evening, and write down the numbers with the date and time

›Call your specialist or return to the emergency department the same day if your top number goes more than 20 points above your usual, or is above 150

›Return immediately for a bad headache, blurred or lost vision, shortness of breath, chest pain, confusion, a seizure, or passing much less urine than normal

›Return the same day for muscle weakness, cramps, palpitations, or a slow heartbeat, which can mean high potassium

›Return if you feel faint or your blood pressure is below 100 on top with dizziness, which can mean the dose is now too strong

›Weigh yourself every morning; report a gain of more than 2 kg over 2 days or new swelling in your legs or face

›Do not take ibuprofen, naproxen, diclofenac, or other anti-inflammatory painkillers at all

›For pain or fever use paracetamol (acetaminophen), up to 1 g every 6 hours and no more than 3 g in 24 hours

›Do not use salt substitutes that contain potassium, and follow the low-salt, potassium-limited diet your dietitian gave you

›Do not start or increase steroid tablets such as prednisone without speaking to your rheumatologist first

›Have your blood tested for kidney function and potassium within 3 to 5 days of leaving hospital, then as your team directs

›Keep your appointments: kidney clinic within 1 week, rheumatology within 1 to 2 weeks

›If you have started dialysis, keep every session; kidney function can still recover over 6 to 24 months, so any decision about a transplant is usually delayed

›Bring your blood pressure diary and all your medicines to every appointment

12References/r22

Guidelines and society statements

›EULAR recommendations for the treatment of systemic sclerosis, 2017 update

›European League Against Rheumatism and EULAR Scleroderma Trials and Research group, Annals of the Rheumatic Diseases, 2017; ACE inhibitors are recommended for the treatment of scleroderma renal crisis

›UK Systemic Sclerosis Study Group best practice guidelines for scleroderma renal crisis

›Lynch BM and colleagues, on behalf of the UK Systemic Sclerosis Study Group, 2016; guidance on definition, monitoring of at-risk patients, and ACE inhibitor management

›2013 ACR/EULAR classification criteria for systemic sclerosis

›van den Hoogen F and colleagues, American College of Rheumatology and European League Against Rheumatism, Arthritis and Rheumatism, 2013

›KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease

›Kidney Disease: Improving Global Outcomes Blood Pressure Work Group, Kidney International, 2021; principles for gradual blood pressure reduction in acute kidney injury

Landmark studies and cohorts

›Outcome of renal crisis in systemic sclerosis in relation to availability of ACE inhibitors

›Steen VD, Costantino JP, Shapiro AP, Medsger TA, Annals of Internal Medicine, 1990; introduction of ACE inhibitors transformed survival from near-uniformly fatal to the majority surviving

›Case-control study of corticosteroids and other drugs that either precipitate or protect from scleroderma renal crisis

›Steen VD, Medsger TA, Arthritis and Rheumatism, 1998; corticosteroid exposure associated with subsequent renal crisis

›Scleroderma renal crisis: patient characteristics and long-term outcomes

›Penn H and colleagues, QJM: An International Journal of Medicine, 2007; single-center cohort describing predictors of death and dialysis dependence and recovery of renal function over time

›Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls

›Guillevin L and colleagues, Rheumatology (Oxford), 2012; multicenter characterization of risk factors and outcomes

›Autoantibodies and the risk of scleroderma renal crisis

›Studies associating anti-RNA polymerase III antibodies with diffuse skin disease and an increased risk of renal crisis, and anti-centromere antibodies with lower risk

›Scleroderma renal crisis and renal involvement in systemic sclerosis

›Woodworth TG and colleagues, Nature Reviews Nephrology, 2016; narrative review of pathophysiology, diagnosis, and management including outcomes on and off dialysis

›Scleroderma renal crisis: a review

›Bose N, Chiesa-Vottero A, Chatterjee S, Seminars in Arthritis and Rheumatism, 2015; clinical review including normotensive renal crisis and differential diagnosis

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed September 13, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.